State Street Corp raised its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 30.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 174,529 shares of the ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.93% of ...
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling ...
2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached - NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASD - GPS Currently ...
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: NASDAQ:SLS), a biopharmaceutical company specializing in cancer therapies, has reached a significant milestone in its Phase 3 REGAL clinical trial ...
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the ...